A new era in chronic spontaneous urticaria: FDA approval of the oral BTK inhibitor remibrutinib

On 30 September 2025, the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib) as the first targeted oral therapy for chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1-antihistamine treatment. This approval marks a major advancement in CSU management, offering a convenient, precision-based alternative to injectable biologics such as omalizumab. CSU is a chronic, relapsing inflammatory skin disorder characterized by recurrent wheals and angioedema, often accompanied by sleep disturbance, emotional distress, and reduced quality of life. The pathophysiology involves abnormal activation of mast cells and basophils through the IgE receptor (FcεRI) and downstream Bruton's tyrosine kinase (BTK) signaling, leading to histamine and cytokine release. Remibrutinib, a potent and selective covalent BTK inhibitor, interrupts this inflammatory cascade at its source, thereby providing upstream control of disease activity. FDA approval was based on Phase III REMIX-1 and REMIX-2 trials, which demonstrated rapid, significant, and sustained improvements in Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), and Hives Severity Score (HSS7) compared with placebo. Approximately one-third of patients achieved complete symptom resolution by week 12, and the drug showed an acceptable safety profile with mostly mild adverse events and no need for routine laboratory monitoring. The introduction of remibrutinib represents a paradigm shift in CSU therapy, transitioning from symptomatic relief toward immune-targeted, patient-friendly oral treatment. Future studies should evaluate long-term safety, real-world efficacy, and cost-effectiveness to fully define its role in personalized CSU management.